Free Trial

Fennec Pharmaceuticals Q4 2022 Earnings Report

Fennec Pharmaceuticals logo
C$8.67 +0.16 (+1.88%)
(As of 12/17/2024 ET)

Fennec Pharmaceuticals EPS Results

Actual EPS
-C$0.35
Consensus EPS
-C$0.33
Beat/Miss
Missed by -C$0.02
One Year Ago EPS
N/A

Fennec Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Fennec Pharmaceuticals Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

DeFi Coin on Verge of Breakout! (Ad)

[FREE BOOK] Can You Make a Fortune in Crypto with $50? Get started now before the market takes off!

Click here to request your free copy NOW!

Fennec Pharmaceuticals Earnings Headlines

Fennec Pharmaceuticals (FENC) Gets a Buy from Craig-Hallum
DeFi Coin on Verge of Breakout!
[FREE BOOK] Can You Make a Fortune in Crypto with $50? Get started now before the market takes off!
Fennec announces three executive appointments
Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc (FRX)
See More Fennec Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fennec Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fennec Pharmaceuticals and other key companies, straight to your email.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals (TSE:FRX) operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

View Fennec Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings